ACADIA Pharmaceuticals Inc (OQ:ACAD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 12830 El Camino Real, Suite 400
SAN DIEGO CA 92130
Tel: 1-858-5582871
Website: https://acadia.com
IR: See website
<
Key People
Stephen R. Davis
Chief Executive Officer, Director
Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Brendan P. Teehan
Chief Operating Officer, Executive Vice President, Head of Commercial
Elizabeth H. Z. Thompson
Executive Vice President and Head of Research and Development
Douglas J. Williamson
Executive Vice President - Research and Development
Albert Kildani
Senior Vice President, Investor Relations and Corporate Communications
Kevin R. Oliver
Senior Vice President, Chief Business Officer
   
Business Overview
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Financial Overview
For the fiscal year ended 31 December 2023, ACADIA Pharmaceuticals Inc revenues increased 40% to $726.4M. Net loss decreased 72% to $61.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income, net increase from $6.6M to $17.2M (income), Stock-Based Compensation in R&D decrease of 23% to $17.4M (expense).
Employees: 597 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $2,295M as of Dec 31, 2023
Annual revenue (TTM): $726.44M as of Dec 31, 2023
EBITDA (TTM): -$67.83M as of Dec 31, 2023
Net annual income (TTM): -$61.29M as of Dec 31, 2023
Free cash flow (TTM): $16.65M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 164,771,521 as of Feb 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.